Ohr Pharmaceutical Data Review Supports the Strong Potential of Its Lead Drug OHR/AVR118 for Cachexia
Links shared publicly online about this topic.
- 1,578total visits
Ohr Pharmaceutical Data Review Supports the Strong Potential of Its Lead Drug OHR/AVR118 for Cachexia
Ohr Pharmaceutical Inc. (OTCBB: OHRP) is developing OHR/AVR118 for treatment of cachexia based on technology acquired earlier this year from Advanced Viral Research Corp. OHR/AVR118 has shown excellent therapeutic efficacy and safety in human clinical trials in over 100 patients with applications for cachexia in Cancer and AIDS patients, as well as Rheumatoid Arthritis. OHR/AVR118
View full resource at marketwire.com
Tags: AIDS, Cancer, Drug, Pharma, Clinical Trial, Safety
Most Recently Shared on November 24, 2009 at 9:20 pm By:
Treating cancer cachexia. http://www.marketwire.com/press-release/Ohr-Pharmaceutical-Inc-1081303.html
Ohr Pharmaceutical Data Review Supports The Strong Potential Of Its Lead Drug OHR/AVR118 For Cachexia
medicalnewstoday.com — “Ohr pharmaceutical inc. (otcbb: ohrp) is developing ohr/avr118 for treatment of cachexia based on technology acquired earlier this year from advanced viral research corp. ohr/avr118 has shown exce” View full resource at medicalnewstoday.com
Most Recently Shared on November 25, 2009 at 10:26 pm By:
Ohr Pharmaceutical Data Review Supports The Strong Potential Of Its Lead Drug OHR/AVR118 For Cachexia: Ohr Phar.. http://bit.ly/8cv07S
Advertisement
